Coya rises on positive data from Alzheimer's disease treatment trial

Coya Therapeutics

07/06/2023 15:45

** Drug developer Coya Therapeutics Inc's shares  COYA.O 
rise 6.5% at $4.6
    ** Co reports additional positive blood biomarker and brain
imaging data for its experimental treatment, COYA 301, in
treating Alzheimer's disease (AD) patients 
    ** Says treatment with COYA 301 demonstrated decrease in
neuroinflammation
    ** Co adds over the open-label study course the treatment
also lowered the levels of biomarkers and a type of
pro-inflammatory proteins in patients
    ** STAA previously reported that COYA 301 in the same study
enhanced the function of regulatory T cells and halted cognitive
decline, when tested on a scale used to measure the severity of
the disease
    ** Co expects to report top-line data from COYA 301's
ongoing mid-stage academic AD trial in Q2 2024
    ** YTD co's stock down 2.5%, including session's gain

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))